Andrea van Elsas is CSO at ADURO BIOTECH, INC. (ADRO). They have made 10 open-market trades across 1 company since 2017, most recently 2020-02-25.
CIK 0001714425
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADRO | 438,367 | $6.4M |
Shares reported on the most recent Form 4, priced at the 2020-02-26 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADRO | SELL | 2020-02-25 | 2020-02-26 | $3.51 | $24K | -9.2% | -24.6% | -5.6% |
| ADRO | SELL | 2020-01-03 | 2020-01-06 | $1.19 | $174K | +0.8% | +106.8% | +115.8% |
| ADRO | SELL | 2019-12-12 | 2019-12-16 | $1.16 | $3K | +6.3% | +10.7% | +104.5% |
| ADRO | SELL | 2019-09-13 | 2019-09-17 | $1.31 | $24K | -21.1% | -18.8% | -16.5% |
| ADRO | SELL · 10b5-1 | 2019-03-19 | 2019-03-21 | $3.96 | $24K | +4.7% | -12.7% | -50.4% |
| ADRO | SELL | 2019-02-26 | 2019-02-27 | $4.25 | $29K | -5.2% | -5.2% | -22.1% |
| ADRO | SELL · 10b5-1 | 2018-12-28 | 2018-12-31 | $2.57 | $5K | +15.5% | +5.4% | +54.3% |
| ADRO | SELL | 2018-12-12 | 2018-12-14 | $2.93 | $6K | -5.2% | +4.4% | +47.2% |
| ADRO | SELL · 10b5-1 | 2018-09-24 | 2018-09-25 | $5.83 | $45K | +0.0% | -30.4% | -58.0% |
| ADRO | SELL | 2018-09-13 | 2018-09-14 | $6.50 | $63K | -11.8% | -6.0% | -59.9% |
| ADRO | SELL | 2018-07-17 | 2018-07-19 | $6.96 | $146K | -17.0% | -14.9% | -11.3% |
| ADRO | SELL | 2018-02-26 | 2018-02-27 | $6.48 | $45K | +38.9% | +47.6% | +33.3% |
| ADRO | SELL | 2017-09-13 | 2017-09-14 | $10.99 | $108K | -5.0% | -14.4% | -25.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.